Literature DB >> 32398247

Fibrous myopathy induced by intramuscular injections of cyclizine.

Rory James Tinker1, Ryan Wiltshire2, Daniel du Plessis3, James B Lilleker4.   

Abstract

A 63-year-old woman was referred to neurology with bilateral severe progressive pain and stiffness in her thighs. The patient had a 3-year history of injecting intramuscular cyclizine into the anterior thigh to treat nausea associated with a longstanding pan-enteric dysmotility syndrome. MRI of the thighs demonstrated fibrotic appearances. A biopsy of the left vastus lateralis and surrounding fascia identified pathology consistent with a fibrous myopathy. The patient was advised to stop intramuscular injections of cyclizine and undergo physiotherapy but she still remained in considerable pain. Although fibrous myopathy occurring as a consequence of recurrent intramuscular drug injections, particularly heroin, has been previously described, this is the first report of fibrous myopathy associated with the use of intramuscular cyclizine. We highlight this rare association and suggest that the long-term use of intramuscular cyclizine be avoided. © BMJ Publishing Group Limited 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  muscle disease; neuroimaging; neurology (drugs and medicines); pain; pathology

Mesh:

Substances:

Year:  2020        PMID: 32398247      PMCID: PMC7222878          DOI: 10.1136/bcr-2019-233544

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  19 in total

1.  Compression neuropathy of the radial nerve due to pentazocine-induced fibrous myopathy.

Authors:  L Y Kim
Journal:  Arch Phys Med Rehabil       Date:  1987-01       Impact factor: 3.966

2.  Muscle fibrosis associated with intramuscular chlorpromazine administration. A preliminary report.

Authors:  R A Brumback; L Empting; M E Susag; R D Staton
Journal:  J Pharm Pharmacol       Date:  1982-08       Impact factor: 3.765

3.  Fibrous myopathy induced by propoxyphene injections.

Authors:  J F Restrepo; R Guzmán; M A Peña; H Lizarazo; O Méndez; F Rondón; A Iglesias
Journal:  J Rheumatol       Date:  1993-03       Impact factor: 4.666

4.  Cyclizine and droperidol have comparable efficacy and side effects during patient-controlled analgesia.

Authors:  J G Laffey; J F Boylan
Journal:  Ir J Med Sci       Date:  2002 Jul-Sep       Impact factor: 1.568

5.  Focal myopathy associated with chronic intramuscular injection of piritramide.

Authors:  P Y Van den Bergh; L Guettat; B C Vande Berg; J J Martin
Journal:  Muscle Nerve       Date:  1997-12       Impact factor: 3.217

6.  Fibrous myopathy. A rheumatic complication of drug abuse.

Authors:  K R Johnson; W A Hsueh; S M Glusman; F C Arnett
Journal:  Arthritis Rheum       Date:  1976 Sep-Oct

Review 7.  Neuronal mechanisms and the treatment of motion sickness.

Authors:  F Schmäl
Journal:  Pharmacology       Date:  2013-04-20       Impact factor: 2.547

Review 8.  Idiopathic inflammatory myositis.

Authors:  Joanna Tieu; Ingrid E Lundberg; Vidya Limaye
Journal:  Best Pract Res Clin Rheumatol       Date:  2016-05-26       Impact factor: 4.098

9.  Aberrant repair and fibrosis development in skeletal muscle.

Authors:  Christopher J Mann; Eusebio Perdiguero; Antonio L Serrano; Yacine Kharraz; Susana Aguilar; Patrizia Pessina; Pura Muñoz-Cánoves
Journal:  Skelet Muscle       Date:  2011-05-04       Impact factor: 4.912

10.  Mixed connective tissue disease: state of the art on clinical practice guidelines.

Authors:  Benjamin Chaigne; Carlo Alberto Scirè; Rosaria Talarico; Tobias Alexander; Zahir Amoura; Tadej Avcin; Lorenzo Beretta; Andrea Doria; Aurelien Guffroy; Vera Guimarães; Éric Hachulla; Thomas Krieg; David Launay; Gemma Lepri; Pia Moinzadeh; Ulf Müller-Ladner; Simona Rednic; Ana Rodrigues; Sander W Tas; Ronald F van Vollenhoven; Ana Vieira; Stefano Bombardieri; João Eurico Fonseca; Ilaria Galetti; Matthias Schneider; Vanessa Smith; Maurizio Cutolo; Marta Mosca; Rebecca Fischer-Betz
Journal:  RMD Open       Date:  2018-10-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.